Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Sponsor
Ottawa Hospital Research Institute
Study ID
NCT06603870
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Catheter-Related Infections
  • Upper Extremity Deep Vein Thrombosis
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apixaban — DRUG
    Apixaban is Health Canada approved for routine treatment and secondary prevention of VTE. Upon enrollment and during follow-up, patients will be managed with a prophylactic dose of apixaban (2.5 mg orally twice daily) as long as either a CVC or active cancer is present. Apixaban will be stopped at the time of CVC removal and when cancer is in remission. Patients will be instructed to contact the study team when their CVC is removed (to determine if apixaban should be continued, based on cancer status at the time), or any thrombotic or bleeding concerns were to occur in between visits. The investigators will record loss to follow-up, drop out, or death during the study.

Study Details

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Key Dates

First listed
Sep 19, 2024
Start date
Dec 19, 2024
Status verified
May 2025
Primary completion
Oct 31, 2029
Completion
Oct 31, 2029

Study Design

Enrollment
330 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apixaban
    2.5 mg twice daily

Primary Outcome Measure

Venous Thromboembolism (VTE) Rate [ Time Frame: 6 months ]

Central Contacts

Related Studies